Facephi Biometria Balance Sheet Health
Financial Health criteria checks 2/6
Facephi Biometria has a total shareholder equity of €12.4M and total debt of €11.5M, which brings its debt-to-equity ratio to 92.5%. Its total assets and total liabilities are €37.9M and €25.5M respectively.
Key information
92.5%
Debt to equity ratio
€11.49m
Debt
| Interest coverage ratio | n/a |
| Cash | €2.13m |
| Equity | €12.42m |
| Total liabilities | €25.51m |
| Total assets | €37.93m |
Recent financial health updates
Recent updates
Cautious Investors Not Rewarding Facephi Biometria, S.A.'s (BME:FACE) Performance Completely
Dec 28
At €1.81, Is Facephi Biometria, S.A. (BME:FACE) Worth Looking At Closely?
Oct 04Investors Will Want Facephi Biometria's (BME:FACE) Growth In ROCE To Persist
Dec 23Would Facephi Biometria (BME:FACE) Be Better Off With Less Debt?
May 20What Does Facephi Biometria, S.A.'s (BME:FACE) Share Price Indicate?
Jan 01When Should You Buy Facephi Biometria, S.A. (BME:FACE)?
Feb 14
We Wouldn't Rely On Facephi Biometria's (BME:FACE) Statutory Earnings As A Guide
Jan 25The Facephi Biometria (BME:FACE) Share Price Is Up 979% And Shareholders Are Delighted
Dec 30Financial Position Analysis
Short Term Liabilities: FACE's short term assets (€19.1M) do not cover its short term liabilities (€21.3M).
Long Term Liabilities: FACE's short term assets (€19.1M) exceed its long term liabilities (€4.2M).
Debt to Equity History and Analysis
Debt Level: FACE's net debt to equity ratio (75.4%) is considered high.
Reducing Debt: FACE's debt to equity ratio has reduced from 189.5% to 92.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if FACE has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if FACE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.